Lantern Pharma INC Form 4 insider transactions

Lantern Pharma Inc. Director D. Jeffrey Keyser acquired 53,844 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc. Director Maria-Luisa Maccecchini was granted 46,152 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc. Director Vijay Chandru was granted 42,307 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc. director Lee Troy Schalop was granted 43,460 stock options at an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc. Director David S. Silberstein was granted 42,307 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc.'s Chief Financial Officer, David R. Margrave, was granted 20,000 stock options with an exercise price of $3.24 per share.

Lantern Pharma's Chief Scientific Officer, Kishor G. Bhatia, was granted 10,000 stock options with an exercise price of $3.24 per share.

Lantern Pharma Inc. Director Vijay Chandru received amended stock options with significantly reduced exercise prices for a total of 12,335 shares.

Lantern Pharma Inc. CEO Panna Sharma's stock option exercise price was significantly reduced from $15 to $5.04 per share through an amendment.

Lantern Pharma's Chief Scientific Officer, Kishor G. Bhatia, had the exercise prices of his stock options significantly reduced through a re-grant.

Lantern Pharma Inc. director D. Jeffrey Keyser had the exercise price of his stock options reduced, making them more favorable.

Lantern Pharma Inc.'s Chief Financial Officer, David R. Margrave, had the exercise price of 104,400 stock options significantly reduced.

Lantern Pharma director David S. Silberstein received amended stock options with significantly reduced exercise prices for a total of 12,335 shares.

Lantern Pharma Inc. Director Lee Troy Schalop was granted 5,000 stock options with an exercise price of $4.46, vesting over 36 months.

A director and significant shareholder of Lantern Pharma Inc., Aaron G.L. Fletcher, along with affiliated Bios funds, reported the sale of 40,000 shares of common stock on June 13, 2025, at a weighted average price of $3.09 per share.

Leslie W. Kreis, a Director and 10% owner of Lantern Pharma Inc., along with affiliated entities, sold a total of 39,000 shares of common stock for approximately $120,510 through pre-arranged trading plans.

A director and 10% owner of Lantern Pharma Inc., Aaron G.L. Fletcher, along with several affiliated Bios Funds, disposed of a total of 61,613 shares of common stock over three days in June 2025.

Leslie W. Kreis, a Director and 10% owner of Lantern Pharma Inc., along with affiliated Bios Funds, reported the sale of 61,613 shares of common stock totaling approximately $208,000 under a Rule 10b5-1 trading plan.

A recent SEC Form 4 filing reveals that Aaron G.L. Fletcher, a Director and 10% owner of Lantern Pharma Inc., along with several affiliated Bios Funds, sold a total of 56,237 shares of common stock over three days in late May 2025.

Entities associated with Leslie W. Kreis, a Director and 10% owner of Lantern Pharma Inc., reported the sale of 56,237 shares of common stock across multiple transactions in late May 2025.

Director D Jeffrey Keyser exercised Series A warrants to purchase 3,832 shares of Lantern Pharma (LTRN) common stock at $3.13 per share.

Lantern Pharma's CEO, Panna Sharma, reports the acquisition of 70,000 stock options exercisable over a 24-month period.

Maria-Luisa Maccecchini, a director at Lantern Pharma Inc., acquired stock options on July 15, 2024.

D. Jeffrey Keyser, a director at Lantern Pharma Inc., acquired 5,000 stock options on July 15, 2024, under the company's 2018 Stock Incentive Plan.

David R. Margrave, CFO of Lantern Pharma Inc., reports the acquisition of 52,000 stock options on July 15, 2024.

Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc., reports the acquisition of stock options.

Director Vijay Chandru received two stock option grants from Lantern Pharma, vesting over 24 and 36 months respectively.

David S. Silberstein, a director of Lantern Pharma Inc., acquired 10,000 stock options on July 15, 2024, under the company's Amended and Restated 2018 Stock Incentive Plan.

Leslie W. Kreis, along with associated entities, reports the sale of Lantern Pharma (LTRN) common stock across multiple transactions on May 23 and 24, 2024.

Multiple Bios Funds, associated with director Aaron G.L. Fletcher, executed sales of Lantern Pharma (LTRN) common stock on May 23 and 24, 2024, at prices ranging from $6.15 to $6.64.